MIT researchers designed an implantable drug-delivery device to help prevent recurrence of glioblastoma. Ultrasound transducers printed onto the device use sound waves to help drugs pass through the blood-brain barrier.

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide — a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 generative AI platform. Among response-evaluable participants with mesothelioma, the results showed a 40.0% objective response rate (ORR) at 130 mg once daily and an 18.2% ORR with a 68.2% disease control rate (DCR) across the dose cohorts. Findings were presented as a Rapid Oral at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid by Melina E. Marmarelis, MD of Abramson Cancer Center, University of Pennsylvania).